NCT02531152View on ClinicalTrials.gov

28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Open Angle Glaucoma -Ocular Hypertension
Interventions
DRUG

Latanoprost

DRUG

SAR366234

Trial Locations (5)

30076

Investigational Site Number 840005, Roswell

33904

Investigational Site Number 840003, Cape Coral

38119

Investigational Site Number 840002, Memphis

49085

Investigational Site Number 840004, Saint Joseph

90301

Investigational Site Number 840001, Inglewood

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY